{"id":61724,"date":"2024-03-06T08:17:36","date_gmt":"2024-03-06T08:17:36","guid":{"rendered":"https:\/\/medsname.com\/taficita\/"},"modified":"2026-05-14T05:13:54","modified_gmt":"2026-05-14T05:13:54","slug":"taficita","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/taficita\/","title":{"rendered":"Taficita"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 R\u0103spuns rapid \u2014 Ce este Taficita?<\/h3>\n<p style=\"margin:0;\"><strong>Taficita<\/strong> con\u021bine <strong>tenofovir alafenamid 25 mg + emtricitabin\u0103 200 mg<\/strong> \u0219i este utilizat pentru profilaxia pre-expunere la HIV (PrEP) la b\u0103rba\u021bi care au rela\u021bii sexuale cu b\u0103rba\u021bi (MSM) \u0219i femei transgender cu risc substan\u021bial. PrEP bazat pe TAF este aprobat pentru preven\u021bia HIV la <strong>b\u0103rba\u021bi cisgender care au rela\u021bii sexuale cu b\u0103rba\u021bi (MSM) \u0219i femei transgender<\/strong> (studiu DISCOVER, 2019) \u2014 nu pentru femei cisgender, unde dovezile din studii sunt insuficiente. Dozare zilnic\u0103; nu este inferioar\u0103 TDF\/FTC, cu siguran\u021b\u0103 renal\u0103 \u0219i osoas\u0103 substan\u021bial mai bun\u0103 (studiu DISCOVER). Produs de Emcure Pharmaceuticals. Sub supraveghere specializat\u0103; necesit\u0103 confirmarea statutului HIV-negativ \u00eenainte de \u00eencepere \u0219i la fiecare 3 luni pe durata terapiei.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f6f7fb;border:1px solid #e3e5ee;border-radius:8px;padding:14px 18px;margin:18px 0;font-size:14px;line-height:1.55;\"><strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Provenit de la un produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare worldwide \u00b7 <a href=\"\/ro\/reviews\/\" rel=\"noopener\">Peste 1.400 de recenzii verificate ale clien\u021bilor<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Comand\u00e2nd de la MedsBase beneficia\u021bi de surs\u0103 de la un produc\u0103tor certificat WHO-GMP, ambalaj discret \u00een plic simplu, livrare worldwide \u0219i evalu\u0103ri de 4.9\u2605 de la peste 1.400 de clien\u021bi verifica\u021bi. Pl\u0103\u021bile cu cardul sunt procesate printr-un on-ramp crypto reglementat \u2014 descriptorul de pe extrasul de cont va afi\u0219a numele procesatorului (un procesator de pl\u0103\u021bi cu card reglementat), niciodat\u0103 \u201cMedsBase\u201d sau nume de medicamente. Fiecare colet este acoperit de <a href=\"\/ro\/medsbase-re-shipment-assurance-policy\/\" rel=\"noopener\">Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a>.<\/p>\n<p><strong>Taficita<\/strong> este un <strong>profilaxie zilnic\u0103 pre-expunere (PrEP) la HIV<\/strong> comprimat combin\u00e2nd <strong>tenofovir alafenamid (TAF) 25 mg<\/strong> \u0219i <strong>emtricitabin\u0103 (FTC) 200 mg<\/strong> \u2014 aceea\u0219i combina\u021bie \u00een doz\u0103 fix\u0103 care alc\u0103tuie\u0219te medicamentul de marc\u0103 Descovy\u00ae dezvoltat ini\u021bial de Gilead Sciences. Taficita este comprimatul tenofovir alafenamid\u0103 + emtricitabin\u0103 al Emcure Pharmaceuticals \u2014 un generic Descovy destinat b\u0103rba\u021bilor care au rela\u021bii sexuale cu b\u0103rba\u021bi (MSM) \u0219i femeilor transgender HIV-negative care doresc PrEP cu profilul \u00eembun\u0103t\u0103\u021bit de siguran\u021b\u0103 renal\u0103 \u0219i osos al prodrogului TAF fa\u021b\u0103 de combina\u021biile mai vechi bazate pe TDF.<\/p>\n<p>TAF este o <strong>form\u0103 mai nou\u0103 de prodrog a tenofovirului<\/strong> dezvoltat\u0103 special pentru a rezolva efectele secundare renale \u0219i osoase ale vechiului tenofovir disoproxil fumarat (TDF). Prin livrarea selectiv\u0103 a tenofovirului c\u0103tre celulele \u021bint\u0103, TAF realizeaz\u0103 o activitate antiviral\u0103 echivalent\u0103 la aproximativ o zecime din expunerea plasmatic\u0103 la tenofovir \u2014 ceea ce \u00eenseamn\u0103 o toxicitate mult mai mic\u0103 pentru rinichi \u0219i oase pe parcursul anilor de utilizare zilnic\u0103.<\/p>\n<h2 class=\"wp-block-heading\">Ce este Taficita?<\/h2>\n<p>Taficita este un comprimat cu combina\u021bie \u00een doz\u0103 fix\u0103 a doi inhibitori nucleozidici\/nucleotidici ai transcriptazei inverse:<\/p>\n<ul>\n<li><strong>Tenofovir alafenamid\u0103 (TAF) 25 mg<\/strong> \u2014 un prodrog al tenofovirului care este activat \u00een principal \u00een interiorul celulelor \u021bint\u0103 (celule infectate cu HIV sau susceptibile la HIV). Asigur\u0103 niveluri intracelulare echivalente de medicament cu TDF, men\u021bin\u00e2nd totodat\u0103 tenofovirul plasmatic cu ~90% mai pu\u021bin<\/li>\n<li><strong>Emtricitabin\u0103 (FTC) 200 mg<\/strong> \u2014 acela\u0219i inhibitor nucleozidic al transcriptazei inverse utilizat \u00een regimurile TDF\/FTC, cu un profil de rezisten\u021b\u0103 complementar celui al TAF<\/li>\n<\/ul>\n<p>Folosit\u0103 ca PrEP, Taficita pre\u00eencarc\u0103 celulele susceptibile la HIV cu inhibitor al transcriptazei inverse, astfel \u00eenc\u00e2t orice virus care p\u0103trunde \u00een urma unei expuneri sexuale nu poate finaliza etapa de transcrip\u021bie invers\u0103 \u0219i, prin urmare, nu poate stabili o infec\u021bie cronic\u0103.<\/p>\n<p><strong>Echivalen\u021b\u0103 clinic\u0103:<\/strong> Taficita \u0219i medicamentul de marc\u0103 Descovy con\u021bin acelea\u0219i substan\u021be active (TAF 25 mg + FTC 200 mg) \u0219i sunt fabricate conform standardelor de bioechivalen\u021b\u0103 stabilite de autorit\u0103\u021bile de reglementare a medicamentelor. Dovedele clinice din studiul DISCOVER (studiu de PrEP cu TAF\/FTC) se aplic\u0103 \u00een mod egal tuturor produc\u0103torilor acestei combina\u021bii de doz\u0103 fix\u0103.<\/p>\n<h2 class=\"wp-block-heading\">TAF vs TDF \u2014 De ce a\u0219 alege acest produs?<\/h2>\n<table>\n<thead>\n<tr>\n<th>Considera\u021bii<\/th>\n<th>TAF\/FTC (acest produs)<\/th>\n<th>TDF\/FTC (<a href=\"\/ro\/tenvir-em\/\" rel=\"noopener\">Tenvir EM<\/a>, etc.)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Siguran\u021b\u0103 renal\u0103<\/strong><\/td>\n<td>Semnificativ mai bun \u2014 expunerea plasmatic\u0103 la tenofovir este cu ~90% mai mic\u0103. Preferat pentru eGFR 30\u201359 mL\/min (unde TDF este contraindica\u021b)<\/td>\n<td>Sc\u0103dere mic\u0103 a eGFR cu utilizare pe termen lung; contraindica\u021b sub eGFR 60 mL\/min<\/td>\n<\/tr>\n<tr>\n<td><strong>Densitatea mineral\u0103 osoas\u0103<\/strong><\/td>\n<td>Avantaj clinic semnificativ \u2014 nu s-a observat o sc\u0103dere semnificativ\u0103 a DMO \u00een studiul DISCOVER. Preferat pentru osteopenie\/osteoporoz\u0103<\/td>\n<td>Sc\u0103dere mic\u0103, dar real\u0103 a DMO, \u00een special \u00een primii 2 ani<\/td>\n<\/tr>\n<tr>\n<td><strong>Popula\u021bii aprobate pentru PrEP<\/strong><\/td>\n<td><strong>Doar b\u0103rba\u021bi care au rela\u021bii sexuale cu b\u0103rba\u021bi (MSM) \u0219i femei transgender<\/strong> (pe baza designului studiului DISCOVER). Nu este aprobat de FDA pentru femei cisgender \u2014 studiul nu le-a inclus<\/td>\n<td>Toate popula\u021biile la risc \u2014 b\u0103rba\u021bi cis, femei cis, persoane trans, consumatori de droguri injectabile (iPrEx, PROUD, Partners PrEP, HPTN 084)<\/td>\n<\/tr>\n<tr>\n<td><strong>Programe de dozare<\/strong><\/td>\n<td>Doar zilnic. Schema la cerere 2-1-1 nu este <strong>validat\u0103<\/strong> pentru TAF<\/td>\n<td>Zilnic sau la cerere 2-1-1 pentru b\u0103rba\u021bi cis-MSM (protocol IPERGAY)<\/td>\n<\/tr>\n<tr>\n<td><strong>Cost<\/strong><\/td>\n<td>De obicei mai mare dec\u00e2t genericele TDF\/FTC<\/td>\n<td>Cea mai ieftin\u0103 op\u021biune de PrEP<\/td>\n<\/tr>\n<tr>\n<td><strong>Modific\u0103ri ale greut\u0103\u021bii<\/strong><\/td>\n<td>S-a observat o u\u0219oar\u0103 cre\u0219tere \u00een greutate (~1\u20132 kg pe an; mecanismul nu este pe deplin \u00een\u021beles)<\/td>\n<td>Neutr\u0103 din punct de vedere al greut\u0103\u021bii sau cu o u\u0219oar\u0103 sc\u0103dere a greut\u0103\u021bii<\/td>\n<\/tr>\n<tr>\n<td><strong>Profil lipidic<\/strong><\/td>\n<td>Cre\u0219te moderat LDL \u0219i colesterolul total<\/td>\n<td>Scade u\u0219or LDL (prin efectul lipidic independent al TDF)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Regul\u0103 practic\u0103 de decizie:<\/strong> dac\u0103 ai func\u021bie renal\u0103 normal\u0103, nu ai probleme de densitate osoas\u0103 \u0219i dore\u0219ti cea mai larg\u0103 indica\u021bie aprobat\u0103 (\u0219i cel mai mic cost), TDF\/FTC ( ) este de prim\u0103 inten\u021b\u0103. Dac\u0103 ai eGFR redus (30\u201359), osteopenie\/osteoporoz\u0103 existent\u0103 sau e\u0219ti un b\u0103rbat cis-MSM sau o femeie transgender care dore\u0219te un profil mai sigur pe termen lung, Taficita este op\u021biunea mai potrivit\u0103.<a href=\"\/ro\/tenvir-em\/\" rel=\"noopener\">Tenvir EM<\/a>Cum func\u021bioneaz\u0103 Taficita ca PrEP.<\/p>\n<h2 class=\"wp-block-heading\">How Taficita Works as PrEP<\/h2>\n<p>Dup\u0103 \u00eenghi\u021bire, TAF este stabil \u00een plasm\u0103 (spre deosebire de TDF care este clivat \u00een s\u00e2nge \u00een tenofovir) \u0219i este preluat selectiv de limfocite, mucoasa intestinal\u0103 \u0219i alte celule \u021bint\u0103 pentru HIV. \u00cen interiorul acestor celule, TAF este convertit de enzimele celulare \u00een metabolitul activ tenofovir difosfat, care concureaz\u0103 cu nucleotidele naturale la nivelul transcriptazei inverse a HIV \u0219i \u00eentrerupe elongarea lan\u021bului de ADN.<\/p>\n<p>Puncte farmacocinetice cheie care afecteaz\u0103 protec\u021bia:<\/p>\n<ul>\n<li><strong>Concentra\u021bia \u00een \u021besutul rectal<\/strong> atinge rapid niveluri protectoare la administrarea zilnic\u0103 \u2014 datele de expunere DISCOVER au ar\u0103tat o protec\u021bie robust\u0103 la b\u0103rba\u021bii care au rela\u021bii sexuale cu b\u0103rba\u021bi (MSM) care iau \u22654 doze pe s\u0103pt\u0103m\u00e2n\u0103<\/li>\n<li><strong>Expunere cervicovaginal\u0103 \u0219i prin injec\u021bie<\/strong> \u2014 TAF\/FTC este <strong>NEAPROBAT de FDA<\/strong> pentru femeile cisgender. Designul studiului DISCOVER nu a inclus femei cis, astfel \u00eenc\u00e2t eficacitatea pentru expunerea prin sex vaginal \u0219i consumul de droguri injectabile nu a fost demonstrat\u0103 formal. Femeile cis care caut\u0103 PrEP ar trebui s\u0103 utilizeze TDF\/FTC (care are date solide din studiile Partners PrEP \u0219i HPTN 084)<\/li>\n<li><strong>Timpul de \u00eenjum\u0103t\u0103\u021bire al tenofovir difosfatului (intracelular)<\/strong> este suficient de lung pentru a tolera o doz\u0103 omis\u0103 ocazional, dar omiterea mai multor doze pe s\u0103pt\u0103m\u00e2n\u0103 reduce semnificativ protec\u021bia<\/li>\n<li><strong>Acoperire post-expunere<\/strong> dup\u0103 ultima expunere: continua\u021bi administrarea timp de cel pu\u021bin 28 de zile dup\u0103 ultima expunere poten\u021bial\u0103 la HIV pentru a acoperi fereastra de incuba\u021bie<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u00cenainte de a \u00eencepe PrEP \u2014 Teste obligatorii<\/h2>\n<p>Cerin\u021bele de testare \u00eenainte de \u00eenceperea terapiei cu TAF\/FTC PrEP sunt identice cu cele pentru TDF\/FTC:<\/p>\n<table>\n<thead>\n<tr>\n<th>Test<\/th>\n<th>De ce este important<\/th>\n<th>Calendar<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Test HIV (antigen\/anticorpi de genera\u021bia a 4-a sau ARN HIV)<\/strong><\/td>\n<td>Trebuie confirmat negativ. \u00cenceperea PrEP \u00een timp ce persoana este infectat\u0103 cu HIV f\u0103r\u0103 s\u0103 \u0219tie poate duce la rezisten\u021b\u0103 (M184V, K65R) care compromite op\u021biunile viitoare de tratament HIV<\/td>\n<td>\u00cen termen de 7 zile de la \u00eencepere<\/td>\n<\/tr>\n<tr>\n<td><strong>Antigenul de suprafa\u021b\u0103 al hepatitei B (HBsAg)<\/strong><\/td>\n<td>TAF\/FTC trateaz\u0103 \u0219i HBV. La pacien\u021bii cu HBV pozitiv, \u00eentreruperea PrEP poate provoca o exacerbare sever\u0103 a hepatitei \u2014 gestiona\u021bi cu consult hepatologic<\/td>\n<td>De baz\u0103<\/td>\n<\/tr>\n<tr>\n<td><strong>Func\u021bia renal\u0103 (creatinin\u0103, eGFR)<\/strong><\/td>\n<td>TAF este mai sigur pentru rinichi dec\u00e2t TDF, dar necesit\u0103 totu\u0219i eGFR \u226530 mL\/min. Sub aceast\u0103 valoare, datele de siguran\u021b\u0103 sunt limitate<\/td>\n<td>La baz\u0103, apoi la fiecare 12 luni (mai rar dec\u00e2t cu TDF)<\/td>\n<\/tr>\n<tr>\n<td><strong>Testare IST (sifilis, clamidie, gonoree)<\/strong><\/td>\n<td>PrEP previne HIV, nu \u0219i alte IST. Testarea de baz\u0103 + screening trimestrial este standardul de \u00eengrijire<\/td>\n<td>De baz\u0103, la fiecare 3 luni<\/td>\n<\/tr>\n<tr>\n<td><strong>Profil lipidic (la baz\u0103 pentru compara\u021bie)<\/strong><\/td>\n<td>TAF\/FTC cre\u0219te u\u0219or LDL \u0219i colesterolul total. Merit\u0103 un profil de baz\u0103 pentru a putea interpreta orice modific\u0103ri<\/td>\n<td>La baz\u0103, apoi dup\u0103 indica\u021bii clinice<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Monitorizare continu\u0103:<\/strong> Test HIV la fiecare 3 luni. Screening IST la fiecare 3 luni. Func\u021bia renal\u0103 cel pu\u021bin anual. Profil lipidic dup\u0103 indica\u021bii clinice. Starea HBV nu trebuie retestat\u0103 dac\u0103 a fost negativ\u0103 la baz\u0103, dec\u00e2t dac\u0103 apar noi factori de risc.<\/p>\n<h2 class=\"wp-block-heading\">Doza<\/h2>\n<p><strong>Zilnic.<\/strong> O tablet\u0103 luat\u0103 la aceea\u0219i or\u0103 \u00een fiecare zi. Spre deosebire de TDF\/FTC, <strong>protocolul la cerere 2-1-1 (IPERGAY) NU este validat pentru TAF\/FTC<\/strong> \u2014 farmacocinetica celular\u0103 distinct\u0103 a TAF nu a fost studiat\u0103 \u00een studiile de dozare la cerere \u0219i nu exist\u0103 dovezi care s\u0103 o sus\u021bin\u0103. Dac\u0103 dori\u021bi flexibilitatea doz\u0103rii la cerere, folosi\u021bi TDF\/FTC (<a href=\"\/ro\/tenvir-em\/\" rel=\"noopener\">Tenvir EM<\/a>) \u00een schimb.<\/p>\n<p><strong>Dac\u0103 omite\u021bi o doz\u0103:<\/strong> lua\u021bi-o c\u00e2nd v\u0103 aminti\u021bi \u00een termen de 24 de ore. Dac\u0103 au trecut mai mult de 24 de ore, omite\u021bi doza ratat\u0103 \u0219i continua\u021bi cu urm\u0103toarea programat\u0103 \u2014 nu lua\u021bi o doz\u0103 dubl\u0103.<\/p>\n<p><strong>Momentul administr\u0103rii \u00een raport cu mesele:<\/strong> poate fi luat cu sau f\u0103r\u0103 alimente. Dac\u0103 greata este o problem\u0103 \u00een primele s\u0103pt\u0103m\u00e2ni, administrarea cu m\u00e2ncare ajut\u0103.<\/p>\n<h2 class=\"wp-block-heading\">Efecte Secundare<\/h2>\n<p>TAF\/FTC este \u00een general mai bine tolerat dec\u00e2t TDF\/FTC, \u00een special \u00een primele s\u0103pt\u0103m\u00e2ni. Majoritatea efectelor secundare apar \u00een primele 2-4 s\u0103pt\u0103m\u00e2ni de \u201cpornire\u201d \u0219i se amelioraz\u0103 cu utilizarea continuat\u0103.<\/p>\n<table>\n<thead>\n<tr>\n<th>Severitate<\/th>\n<th>Efect Secundar<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Frecvente, tranzitorii<\/strong><\/td>\n<td>Grea\u021b\u0103 u\u0219oar\u0103, diaree, disconfort abdominal, cefalee. \u00cen general mai pu\u021bin intense dec\u00e2t cu TDF<\/td>\n<\/tr>\n<tr>\n<td><strong>Mai pu\u021bin frecvent\u0103<\/strong><\/td>\n<td>Cre\u0219terea \u00een greutate (aproximativ 1-2 kg pe parcursul unui an), cre\u0219tere moderat\u0103 a LDL \u0219i a colesterolului total, ame\u021beli, insomnie, erup\u021bii cutanate<\/td>\n<\/tr>\n<tr>\n<td><strong>Rare, dar grave<\/strong><\/td>\n<td>Acidoz\u0103 lactic\u0103, cre\u0219tere sever\u0103 a enzimelor hepatice, steatoz\u0103 hepatic\u0103, reac\u021bie alergic\u0103 sever\u0103. Cere\u021bi ajutor medical urgent pentru oboseal\u0103 sever\u0103, dureri musculare neexplicate, grea\u021b\u0103 persistent\u0103 sau icter<\/td>\n<\/tr>\n<tr>\n<td><strong>Specifice HBV<\/strong><\/td>\n<td>\u00centreruperea brusc\u0103 a TAF\/FTC la pacien\u021bii HBV-pozitivi poate declan\u0219a o exacerbare acut\u0103 a hepatitei - poten\u021bial periculoas\u0103 pentru via\u021b\u0103. Pacien\u021bii HBV-pozitivi \u00een regim PrEP <strong>nu trebuie s\u0103 \u00eentrerup\u0103 brusc<\/strong> f\u0103r\u0103 implicarea unui hepatolog<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>\u00cen compara\u021bie cu TDF\/FTC:<\/strong> toxicitate renal\u0103 mai mic\u0103, sc\u0103dere mai mic\u0103 a densit\u0103\u021bii minerale osoase, efecte u\u0219or mai mari asupra greut\u0103\u021bii \u0219i lipidelor, tolerabilitate gastrointestinal\u0103 similar\u0103, considera\u021bii identice pentru HBV.<\/p>\n<h2 class=\"wp-block-heading\">Contraindica\u021bii \u0219i precau\u021bii<\/h2>\n<ul>\n<li><strong>Statut HIV-pozitiv confirmat<\/strong> \u2014 TAF\/FTC este un regim cu 2 medicamente care este sub-terapeutic pentru tratamentul HIV; utilizarea lui selecteaz\u0103 muta\u021bii de rezisten\u021b\u0103 care compromit op\u021biunile viitoare de tratament<\/li>\n<li><strong>eGFR sub 30 mL\/min<\/strong> \u2014 datele de siguran\u021b\u0103 \u0219i eficacitate sunt limitate; se recomand\u0103 consult specializat<\/li>\n<li><strong>Hepatit\u0103 acut\u0103<\/strong> \u2014 utiliza\u021bi cu precau\u021bie \u0219i consulta\u021bi un hepatolog<\/li>\n<li><strong>Al\u0103ptare<\/strong> \u2014 tenofovirul este secretat \u00een laptele matern. Secre\u021bia de TAF este mai mic\u0103 dec\u00e2t cea de TDF, dar se recomand\u0103 evaluarea risc\/beneficiu cu un clinician<\/li>\n<li><strong>Femei care caut\u0103 PrEP pentru expunere vaginal\u0103\/frontal\u0103<\/strong> \u2014 utiliza\u021bi TDF\/FTC \u00een schimb; TAF\/FTC nu are aprobare regulatorie sau date din studii pentru aceast\u0103 popula\u021bie<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<ul>\n<li><strong>Rifampin\u0103, rifabutin\u0103, carbamazepin\u0103, fenitoin\u0103, sun\u0103toarea<\/strong> \u2014 inductori puternici ai enzimelor care activeaz\u0103 TAF. <strong>Contraindica\u021bii<\/strong> sau necesit\u0103 ajustare de doz\u0103; consulta\u021bi un clinician<\/li>\n<li><strong>Medicamente nefrotoxice<\/strong> (aminoglicozide, amfotericin\u0103 B, cidofovir, pentamidin\u0103 IV) \u2014 tot merit\u0103 evitate \u00een ciuda profilului renal mai bun al TAF<\/li>\n<li><strong>Didanosine (ddI)<\/strong> \u2014 evita\u021bi combinarea (preocup\u0103ri istorice de co-toxicitate din epoca TDF, date limitate pentru TAF dar precau\u021bie justificat\u0103)<\/li>\n<li><strong>Regimuri de profilaxie post-expunere la HIV (PEP)<\/strong> \u2014 dac\u0103 este necesar PEP dup\u0103 expunere de risc ridicat, gestiona\u021bi \u00eempreun\u0103 cu un specialist \u00een HIV<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Cum s\u0103 lua\u021bi Taficita \u2014 Ghid practic<\/h2>\n<ul>\n<li>\u00cenghi\u021bi\u021bi comprimatul \u00eentreg cu ap\u0103, <strong>la aceea\u0219i or\u0103 \u00een fiecare zi<\/strong>. Lipsa a mai mult de 1\u20132 doze pe s\u0103pt\u0103m\u00e2n\u0103 reduce semnificativ protec\u021bia<\/li>\n<li>Poate fi luat cu sau f\u0103r\u0103 m\u00e2ncare<\/li>\n<li>Dac\u0103 a\u021bi uitat s\u0103 lua\u021bi o doz\u0103 \u0219i v\u0103 aminti\u021bi \u00een decurs de 24 de ore, lua\u021bi-o c\u00e2t mai cur\u00e2nd posibil; altfel omite\u021bi doza uitat\u0103<\/li>\n<li>Nu <strong>prime\u0219te,<\/strong> opri\u021bi brusc PrEP dac\u0103 sunte\u021bi HBV-pozitiv f\u0103r\u0103 consult medical<\/li>\n<li>Continua\u021bi cel pu\u021bin 28 de zile dup\u0103 ultima expunere sexual\u0103 (coad\u0103 de 2 doze) pentru a acoperi fereastra de incuba\u021bie<\/li>\n<li>Reveni\u021bi trimestrial pentru teste HIV \u0219i ITS; anual pentru panel renal \u0219i lipidic<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<ul>\n<li>P\u0103stra\u021bi la sub 30\u00b0C \u00eentr-un loc r\u0103coros \u0219i uscat<\/li>\n<li>P\u0103stra\u021bi \u00een ambalajul original sau \u00een blister p\u00e2n\u0103 la utilizare<\/li>\n<li>Nu utiliza\u021bi dup\u0103 data de expirare tip\u0103rit\u0103 pe ambalaj<\/li>\n<li>Depozita\u021bi \u00eentr-un loc inaccesibil copiilor \u0219i animalelor de companie<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Op\u021biuni conexe de PrEP pe MedsBase<\/h2>\n<ul>\n<li><a href=\"\/ro\/tenvir-em\/\" rel=\"noopener\"><strong>Tenvir EM<\/strong><\/a> \u2014 TDF\/FTC de la Cipla (generic Truvada). Pagina noastr\u0103 de PrEP cea mai recomandat\u0103. Aprobat\u0103 pentru toate popula\u021biile la risc, inclusiv femeile cis<\/li>\n<li><a href=\"\/ro\/ricovir-em\/\" rel=\"noopener\"><strong>Ricovir EM<\/strong><\/a> \u2014 alternativ\u0103 TDF\/FTC de la Mylan\/Viatris<\/li>\n<li><a href=\"\/ro\/tavin-em\/\" rel=\"noopener\"><strong>Tavin EM<\/strong><\/a> \u2014 alternativ\u0103 TDF\/FTC de la Emcure<\/li>\n<li><a href=\"\/ro\/tenof-em\/\" rel=\"noopener\"><strong>Tenof EM<\/strong><\/a> \u2014 alternativ\u0103 TDF\/FTC de la Hetero<\/li>\n<li><a href=\"\/ro\/std-protection-pack\/\" rel=\"noopener\"><strong>Pachet Protec\u021bie IST<\/strong><\/a> \u2014 TDF\/FTC + doxiciclin\u0103 (DoxyPEP) + azitromicina pentru o acoperire mai larg\u0103 a s\u0103n\u0103t\u0103\u021bii sexuale<\/li>\n<\/ul>\n<p>Vede\u021bi \u0219i <a href=\"\/ro\/hiv-medication\/\">Medicamente HIV<\/a> \u0219i <a href=\"\/ro\/sexual-health\/\">S\u0103n\u0103tate sexual\u0103<\/a> categorii.<\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">Este Taficita la fel cu Descovy?<\/h3>\n<p>Echivalent clinic. Taficita con\u021bine exact acelea\u0219i ingrediente active ca Descovy\u00ae (tenofovir alafenamid\u0103 25 mg + emtricitabin\u0103 200 mg) \u0219i este produs\u0103 conform standardelor de bioechivalen\u021b\u0103 farmaceutic\u0103. Dovezile clinice din studiul DISCOVER care sus\u021bin PrEP cu TAF\/FTC se aplic\u0103 tuturor genericulor bioechivalente ale acestei combina\u021bii \u00een doz\u0103 fix\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Pot folosi Taficita dac\u0103 sunt femeie cisgender?<\/h3>\n<p><strong>Nu ca tratament de prim\u0103 linie.<\/strong> TAF\/FTC este aprobat pentru PrEP doar la b\u0103rba\u021bii cisgender MSM \u0219i femeile transgender, deoarece studiul DISCOVER nu a inclus femei cisgender. Dac\u0103 sunte\u021bi o femeie cisgender care caut\u0103 PrEP, TDF\/FTC (de exemplu <a href=\"\/ro\/tenvir-em\/\" rel=\"noopener\">Tenvir EM<\/a>) are dovezi puternice din studiile Partners PrEP \u0219i HPTN 084 \u0219i este alegerea corect\u0103 de prim\u0103 linie.<\/p>\n<h3 class=\"wp-block-heading\">C\u00e2t de eficient este Taficita \u00een compara\u021bie cu TDF\/FTC?<\/h3>\n<p>Studiul DISCOVER (2019) a ar\u0103tat c\u0103 TAF\/FTC este <strong>neinferior<\/strong> fa\u021b\u0103 de TDF\/FTC pentru preven\u021bia HIV la MSM \u0219i femei transgender, cu <strong>o siguran\u021b\u0103 renal\u0103 \u0219i osoas\u0103 mai bun\u0103<\/strong>. Ambele regimuri reduc riscul de HIV cu &gt;99% la aderen\u021b\u0103 ridicat\u0103.<\/p>\n<h3 class=\"wp-block-heading\">De ce a\u0219 pl\u0103ti mai mult pentru Taficita fa\u021b\u0103 de un generic TDF?<\/h3>\n<p>Dou\u0103 motive principale: (1) impact semnificativ mai mic asupra func\u021biei renale \u0219i densit\u0103\u021bii osoase, ceea ce conteaz\u0103 dac\u0103 pl\u0103nui\u021bi s\u0103 fi\u021bi pe PrEP pentru mul\u021bi ani sau ave\u021bi factori de risc existen\u021bi; (2) ave\u021bi insuficien\u021b\u0103 renal\u0103 de baz\u0103 (eGFR 30\u201359 mL\/min) unde TDF este contraindicat. Pentru utilizatorii s\u0103n\u0103to\u0219i f\u0103r\u0103 aceste considera\u021bii, TDF\/FTC este la fel de eficient \u0219i mai ieftin.<\/p>\n<h3 class=\"wp-block-heading\">Pot lua Taficita pe un program \u201cla cerere\u201d?<\/h3>\n<p><strong>Nu.<\/strong> Protocolul 2-1-1 (la cerere) este <strong>validat\u0103<\/strong> pentru TAF. Doar dozarea zilnic\u0103 este sus\u021binut\u0103 de dovezi. Dac\u0103 dori\u021bi dozare la cerere \u0219i sunte\u021bi b\u0103rbat cisgender MSM, folosi\u021bi TDF\/FTC \u00een schimb \u2014 datele din IPERGAY \u0219i Prevenir sus\u021bin protocolul 2-1-1 pentru TDF\/FTC.<\/p>\n<h3 class=\"wp-block-heading\">\u0218i despre cre\u0219terea \u00een greutate?<\/h3>\n<p>TAF\/FTC este asociat cu cre\u0219teri mici de greutate \u00een studii (~1\u20132 kg pe an). Mecanismul nu este pe deplin \u00een\u021beles. Pentru majoritatea utilizatorilor acest lucru este nesemnificativ din punct de vedere clinic, dar reprezint\u0103 o diferen\u021b\u0103 real\u0103 fa\u021b\u0103 de TDF\/FTC, care tinde s\u0103 fie neutr\u0103 din punct de vedere al greut\u0103\u021bii.<\/p>\n<h3 class=\"wp-block-heading\">Mai am nevoie de prezervative?<\/h3>\n<p><strong>Yes.<\/strong> PrEP previne doar HIV-ul. Prezervativele reduc riscul altor infec\u021bii cu transmitere sexual\u0103 (clamidioz\u0103, gonoree, sifilis, herpes, HPV, mpox) \u0219i sarcina. PrEP + prezervative + screening trimestrial pentru ITS + vaccin\u0103ri (HPV, hepatit\u0103 A, hepatit\u0103 B dac\u0103 nu e\u0219ti imun) formeaz\u0103 \u00eempreun\u0103 o strategie complet\u0103 de s\u0103n\u0103tate sexual\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Ce se \u00eent\u00e2mpl\u0103 dac\u0103 opresc Taficita?<\/h3>\n<p>Dac\u0103 e\u0219ti HIV-negativ \u0219i HBV-negativ, po\u021bi opri \u00een siguran\u021b\u0103 dup\u0103 o perioad\u0103 de 28 de zile de la ultima expunere la HIV. Dac\u0103 e\u0219ti HBV-pozitiv, <strong>nu opri\u021bi f\u0103r\u0103 implicarea clinicianului<\/strong> \u2014 \u00eentreruperea brusc\u0103 a TAF \u00een HBV cronic poate declan\u0219a o exacerbare acut\u0103 a hepatitei.<\/p>\n<h3 class=\"wp-block-heading\">Pot s\u0103 trec de la TDF\/FTC la Taficita?<\/h3>\n<p>Da, iar aceasta este o decizie clinic\u0103 frecvent\u0103 atunci c\u00e2nd func\u021bia renal\u0103 scade, apar probleme de densitate osoas\u0103 sau se prioritizeaz\u0103 siguran\u021ba pe termen lung. Trecerea ar trebui gestionat\u0103 de un clinician cu teste de urm\u0103rire adecvate.<\/p>\n<h3 class=\"wp-block-heading\">Este Taficita disponibil\u0103 f\u0103r\u0103 prescrip\u021bie medical\u0103?<\/h3>\n<p><strong>Nu.<\/strong> PrEP este un regim supravegheat de speciali\u0219ti care necesit\u0103 confirmarea st\u0103rii de HIV-negativ la baz\u0103, teste de func\u021bie renal\u0103 \u0219i HBV, \u0219i urm\u0103rire la fiecare 3 luni. Nu \u00eencepe PrEP f\u0103r\u0103 confirmarea clinicianului privind starea de HIV-negativ \u0219i testele de baz\u0103 de siguran\u021b\u0103.<\/p>\n<p><!-- medsbase-faq-h3-converted --><\/p>\n<p class=\"medsbase-bundle-link-2026-05-01\" data-marker=\"mb-bundle-link-prep-starter-pack\">Taficita (TAF\/FTC) acoper\u0103 doar HIV PrEP; pentru regimul stratificat PrEP + ITS bacteriene, consulta\u021bi oferta noastr\u0103 <a href='\/ro\/prep-starter-pack\/'>Pachetul de pornire PrEP (Tenvir-EM + doxiciclin\u0103 100 mg)<\/a> \u2014 combina\u021bia stabilit\u0103 TDF\/FTC PrEP \u00eempreun\u0103 cu acoperire doxi-PEP la un pre\u021b combinat mai mic.<\/p>\n<p class=\"medsbase-link-boost-2026-05-08\" data-marker=\"mb-link-boost-tenvir-em\">Persoanele care \u00eencep PrEP \u0219i nu au acces la preparate pe baz\u0103 de TAF <a href=\"https:\/\/medsbase.com\/ro\/taficita\/\">Taficita<\/a> pot lua \u00een considerare <a href=\"https:\/\/medsbase.com\/ro\/tenvir-em\/\">Tenvir EM (tenofovir disoproxil fumarat 300 mg + emtricitabin\u0103 200 mg)<\/a> ca alternativ\u0103 clinic echivalent\u0103 TDF\/FTC, cu acela\u0219i program de administrare o dat\u0103 pe zi \u0219i date de eficacitate pe termen lung echivalente pentru PrEP.<\/p>\n<p class=\"medsbase-link-boost-2026-05-10\" data-marker=\"mb-link-boost-avonza\">Medicii care evalueaz\u0103 op\u021biunile mai vechi pe baz\u0103 de TDF al\u0103turi de <a href=\"https:\/\/medsbase.com\/ro\/taficita\/\">Taficita (tenofovir alafenamid 25 mg + emtricitabin\u0103 200 mg)<\/a> fac adesea referire la <a href=\"https:\/\/medsbase.com\/ro\/avonza\/\">Avonza (TDF \/ lamivudin\u0103 \/ efavirenz)<\/a> ca benchmark stabilit anterior atunci c\u00e2nd evalueaz\u0103 accesibilitatea costurilor \u00een medii cu resurse limitate.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2 id=\"related-alts\">Alte Medicamente pentru S\u0103n\u0103tate Sexual\u0103<\/h2>\n<ul>\n<li><a href=\"\/ro\/tenvir-em\/\">Tenvir EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/ro\/ricovir-em\/\">Ricovir EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/ro\/tenof-em\/\">Tenof EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/ro\/tavin-em\/\">Tavin EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/ro\/std-protection-pack\/\">Pachet Protec\u021bie IST<\/a><\/li>\n<\/ul>\n<p style=\"font-size:13px;color:#555;margin:14px 0;font-style:italic;\"><strong>Disclaimer medical:<\/strong> Informa\u021biile de pe aceast\u0103 pagin\u0103 au doar scop educa\u021bional \u0219i nu \u00eenlocuiesc sfatul medical. Consulta\u021bi \u00eentotdeauna un medic calificat \u00eenainte de a \u00eencepe, \u00eentrerupe sau modifica orice tratament medicamentos.<\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Tratament HIV<br \/>\n\u2705 Reduce \u00eenc\u0103rc\u0103tura viral\u0103<br \/>\n\u2705 Stimuleaz\u0103 sistemul imunitar<br \/>\n\u2705 Reduce riscul de transmitere<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te speran\u021ba de via\u021b\u0103<\/p>\n<p>Taficita con\u021bine Emtricitabine \u0219i Tenofovir.<\/p>","protected":false},"featured_media":61725,"comment_status":"closed","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3304,3338],"product_tag":[5827,5819,3339,5674,5815,5816,5354,5825,5826,5083,4920],"class_list":{"0":"post-61724","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hiv-medication","9":"product_cat-prep-medication-pre-exposure-prophylaxis","10":"product_tag-descovy-generic","11":"product_tag-emcure-pharmaceuticals","12":"product_tag-emtricitabine","13":"product_tag-ftc","14":"product_tag-hiv-prevention","15":"product_tag-pre-exposure-prophylaxis","16":"product_tag-prep","17":"product_tag-taf","18":"product_tag-taf-ftc","19":"product_tag-taficita","20":"product_tag-tenofovir-alafenamide","22":"first","23":"instock","24":"shipping-taxable","25":"purchasable","26":"product-type-variable","27":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/61724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=61724"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/61725"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=61724"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=61724"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=61724"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=61724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}